Two Sigma Advisers
INDV icon

Two Sigma Advisers’s Indivior Pharmaceuticals INDV Stock Holding History

Two Sigma Advisers’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,700
Closed -$886K – 1038
2025
Q4 		$886K Buy
+24,700
New +$754K ﹤0.01% 1546
2025
Q1 		– Sell
-21,700
Closed -$270K – 2479
2024
Q4 		$270K Sell
21,700
-4,700
-18% -$48.4K ﹤0.01% 2023
2024
Q3 		$257K Buy
26,400
+5,300
+25% +$62.1K ﹤0.01% 1975
2024
Q2 		$340K Buy
+21,100
New +$381K ﹤0.01% 2019

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers's INDV Position: Q1 2026 in Review

Two Sigma Advisers sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 24,700 shares — an estimated $886K sold.

Two Sigma Advisers first reported a position in INDV in Q2 2024 and held it in 4 quarters. The position peaked at $886K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Two Sigma Advisers reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 24,700 Indivior Pharmaceuticals shares in Q1 2026, an estimated $886K.
  • Two Sigma Advisers first reported a position in Indivior Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Two Sigma Advisers's Indivior Pharmaceuticals position peaked at $886K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.